SELLAS Life Sciences Group, Inc. Contractual Obligation, to be Paid, Year Five
SELLAS Life Sciences Group, Inc. (SLS) had Contractual Obligation, to be Paid, Year Five of $3.20 million as of 2015-12-31, per its 10-K/A filed 2016-04-15.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity › Contractual Obligation, to be Paid, Year Four and Five
us-gaap:ContractualObligationDueInFifthYear · last filed 2016-04-15
- 2015-12-31: Contractual Obligation, to be Paid, Year Five $3.20M.
- 2014-12-31: Contractual Obligation, to be Paid, Year Five $6.82M.
- 2013-12-31: Contractual Obligation, to be Paid, Year Five $6.93M.
- 2012-12-31: Contractual Obligation, to be Paid, Year Five $350.00K.
| Period end | Contractual Obligation, to be Paid, Year Five |
|---|---|
| 2015-12-31 | $3.20M 10-K/A · filed 2016-04-15 |
| 2014-12-31 | $6.82M 8-K · filed 2015-12-04 |
| 2013-12-31 | $6.93M 10-K · filed 2014-03-17 |
| 2012-12-31 | $350.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |